Computational pharmacokinetics during developmental windows of susceptibility

Journal of Toxicology and Environmental Health - Part A

Volumn 68, Issue 11-12, 2005, Pages 889-900

  Barton, Hugh A ^a  

^a U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA FETOPROTEIN; CYTOCHROME P450 2E1; ESTROGEN; FLUOROURACIL; GLOBULIN; METHANOL; OROSOMUCOID; PERCHLORATE; POLYCHLORINATED BIPHENYL DERIVATIVE; RETINOID; XENOBIOTIC AGENT;

AGE; BIOLOGY; CHILD GROWTH; COMPUTER MODEL; CONFERENCE PAPER; DISEASE PREDISPOSITION; HUMAN; LIFE CYCLE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; METABOLISM; NONHUMAN; PHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; DANGEROUS GOODS; FEMALE; METHODOLOGY; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE;

ANIMALIA; RODENTIA;

AGE FACTORS; ANIMALS; COMPUTER SIMULATION; FEMALE; HAZARDOUS SUBSTANCES; HUMANS; MODELS, BIOLOGICAL; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RISK ASSESSMENT; SPECIES SPECIFICITY;

EID: 23644438904     PISSN: 15287394     EISSN: 10872620     Source Type: Journal    
DOI: 10.1080/15287390590912180     Document Type: Conference Paper

References (72)

1. Alcorn, J., and McNamara, P. J. 2002a. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part I. Clin, Pharmacokinet. 41:959-998.
2. Alcorn, J., and McNamara, P. J. 2002b. Ontogeny of hepatic and renal systemic clearance pathways in infants: Part II. Clin, Pharmacokinet. 41:1077-1094.
3. Alcorn, J., and McNamara, P. J. 2003. Pharmacokinetics in the newborn. Adv. Drug Deliv. Rev. 55:667-686.
4. Anderson, L. M., Diwan, B. A., Fear, N. T., and Roman, E. 2000. Critical windows of exposure for children's health: Cancer in human epidemiological studies and neoplasms in experimental animal models. Environ. Health Perspect. 108(suppl. 3):573-594.
5. Barton, H. A., Andersen, M. E., and Clewell, H. J. III. 1998. Harmonization: Developing consistent guidelines for applying mode of action and dosimetry information to cancer and noncancer risk assessment. Hum. Ecol. Risk Assess. 4:75-115.
6. Barton, H. A., and Clewell, H. J. 3rd. 2000. Evaluating noncancer effects of trichloroethylene: Dosimetry, mode of action, and risk assessment. Environ. Health Perspect. 108(suppl. 2):323-334.
7. Beckman, D. A., and Feuston, M. 2003. Landmarks in the development of the female reproductive system. Birth Defects Res. B Dev. Reprod. Toxicol. 68:137-143.
8. Birnbaum, L. S., and Fenton, S. E. 2003. Cancer and developmental exposure to endocrine disruptors. Environ. Health Perspect. 111:389-394.
9. Bouchard, M., Brunet, R. C., Droz, P. O., and Carrier, G. 2001. A biologically based dynamic model for predicting the disposition of methanol and its metabolites in animals and humans. Toxicol Sci. 64:169-184.
10. Chhabra, R. S., Eustis, S., Haseman, J. K., Kurtz, P. J., and Carlton, B. D. 1992. Comparative carcinogenicity of ethylene thiourea with or without perinatal exposure in rats and mice. Fundam. Appl. Toxicol. 18:405-417.
11. Chhabra, R. S., Bucher, J. R., Haseman, J. K., Elwell, M. R., Kurtz, P. J., and Carlton, B. D. 1993a. Comparative carcinogenicity of 5,5-diphenylhydantoin with or without perinatal exposure in rats and mice. Fundam. Appl. Toxicol. 21:174-186.
12. Chhabra, R. S., Bucher, J. R., Haseman, J. K., Hwell, M. R., Kurtz, P. J., and Carlton, B. D. 1993b. Comparative carcinogenicity of polybrominated biphenyls with or without perinatal exposure in rats and mice. Fundam. Appl. Toxicol. 21:451-460.
13. Clewell, H. J., Andersen, M. E., Wills, R. J., and Latriano, L. 1997. A physiologically based pharmacokinetic model for retinoic acid and its metabolites. J. Am. Acad. Dermatol. 36:S77-S85.
14. Clewell, H. J. 3rd, Andersen, M. E., and Barton, H. A. 2002a. A consistent approach for the application of pharmacokinetic modeling in cancer and noncancer risk assessment. Environ. Health Perspect. 110:85-93.
15. Clewell, H. J., Teeguarden, J., McDonald, T., Sarangapani, R., Lawrence, G., Covington, T., Gentry, R., and Shipp, A. 2002b. Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Crit. Rev. Toxicol. 32:329-389.
16. Clewell, R. A., Merrill, E. A., Yu, K. O., Mahle, D. A., Sterner, T. R., Fisher, J. W., and Gearhart, J. M. 2003a. Predicting neonatal perchlorate dose and inhibition of iodide uptake in the rat during lactation using physiologically-based pharmacokinetic modeling. Toxicol. Sci. 74:416-436.
17. Clewell, R. A., Merrill, E. A., Yu, K. O., Mahle, D. A., Sterner, T. R., Mattie, D. R., Robinson, P. J., Fisher, J. W., and Gearhart, J. M. 2003b. Predicting fetal perchlorate dose and inhibition of iodide kinetics during gestation: A physiologically-based pharmacokinetic analysis of perchlorate and iodide kinetics in the rat. Toxicol. Sci. 73:235-255.
18. Clewell, H. J., Gentry, P. R., Covington, T. R., Sarangapani, R., and Teeguarden, J. G. 2004. Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry. Toxicol. Sci. 79:381-393
19. Collier, J. R., Monk, N. A., Maini, P. K., and Lewis, J. H. 1996. Pattern formation by lateral inhibition with feedback: A mathematical model of delta-notch intercellular signalling. J. Theor. Biol. 183:429-446.
20. Collier, J. R., McInerney, D., Schnell, S., Maini, P. K., Gavaghan, D. J., Houston, P., and Stern, C. D. 2000. A cell cycle model for somitogenesis: Mathematical formulation and numerical simulation. J. Theor. Biol. 207:305-316.
21. Corley, R. A., Mast, T. J., Carney, E. W., Rogers, J. M., and Daston, G. P. 2003. Evaluation of physiologically based models of pregnancy and lactation for their application in children's health risk assessments. Crit. Rev. Toxicol. 33:137-211.
22. Crofton, K. M., Kodavanti, P. R., Derr-Yellin, E. C., Casey, A. C., and Kehn, L. S. 2000. PCBs, thyroid hormones, and ototoxicity in rats: Cross-fostering experiments demonstrate the impact of postnatal lactation exposure. Toxicol. Sci. 57:131-140.
23. Daston, G. P. 1993. Do thresholds exist for developmental toxicants? A review of the theoretical and experimental evidence. In Issues and reviews in teratology, vol. 6, ed. H. Kalter, pp. 169-197. New York: Plenum Press.
24. Daston, G., Faustman, E., Ginsberg, G., Fenner-Crisp, P., Olin, S., Sonawane, B., Bruckner, J., Breslin, W., and McLaughlin, T. J. 2004. A framework for assessing risks to children from exposure to environmental agents. Environ. Health Perspect. 112:238-256.
25. Della Porta, G., and Terracini, B. 1969. Chemical carcinogenesis in infant animals. Prog. Exp. Tumor Res. 11:334-363.
26. Dietert, R. R., Etzel, R. A., Chen, D., Halonen, M., Holladay, S. D., Jarabek, A. M., Landreth, K., Peden, D. B., Pinkerton, K., Smialowicz, R. J., and Zoetis, T. 2000. Workshop to identify critical windows of exposure for children's health: Immune and respiratory systems work group summary. Environ. Health Perspect. 108(suppl.3):483-490.
27. Dorman, D. C., Allen, S. L., Byczkowski, J. Z., Claudio, L., Fisher, J. E., Jr., Fisher, J. W., Harry, G. J., Li, A. A., Makris, S. L., Padilla, S., Sultatos, L. G., and Mileson, B. E. 2001. Methods to identify and characterize developmental neurotoxicity for human health risk assessment. III: Pharmacokinetic and pharmacodynamic considerations. Environ. Health Perspect. 109(suppl. 1):101-111.
28. Dorne, J. L., Walton, K., and Renwick, A. G. 2001. Human variability in glucuronidation in relation to uncertainty factors for risk assessment. Food Chem. Toxicol. 39:1153-173.
29. Dorne, J. L., Walton, K., Slob, W., and Renwick, A. G. 2002. Human variability in polymorphic CYP2D6 metabolism: Is the kinetic default uncertainty factor adequate? Food Chem. Toxicol. 40:1633-1656.
30. Dourson, M. L., Knauf, L. A., and Swartout, J. C. 1992. On reference dose (RfD) and its underlying toxicity data base. Toxicol. Ind. Health 8:171-189.
31. Emond, C., Birnbaum, L. S., and DeVito, M. J. 2004. Physiologically based pharmacokinetic model for developmental exposures to TCDD in the rat. Toxicol. Sci. 80:115-133.
32. Ferrell, J. E., Jr., and Machleder, E. M. 1998. The biochemical basis of an all-or-none cell fate switch in Xenopus oocytes. Science 280:895-898.
33. Gentry, P. R., Covington, T. R., and Clewell, H. J. 3rd. 2003. Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation. Regul. Toxicol. Pharmacol. 38:1-16.
34. Ginsberg, G., Hattis, D., Sonawane, B., Russ, A., Banati, P., Kozlak, M., Smolenski, S., and Goble, R. 2002. Evaluation of child/adult pharmacokinetic differences from a database derived from the therapeutic drug literature. Toxicol Sci. 66:185-200.
35. Ginsberg, G., Hattis, D., Russ, A., and Sonawane, B. 2004. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Health A 67:297-329.
36. Gray, R., Peto, R., Brantom, P., and Grasso, P. 1991. Chronic nitrosamine ingestion in 1040 rodents: The effect of the choice of nitrosamine, the species studied, and the age of starting exposure. Cancer Res. 51:6470-6491.
37. Haddad, S., Restieri, C., and Krishnan, K. 2001. Characterization of age-related changes in body weight and organ weights from birth to adolescence in humans. J. Toxicol. Environ. Health A 64:453-464.
38. Hattis, D., Ginsberg, G., Sonawane, B., Smolenski, S., Russ, A., Kozlak, M., and Goble, R. 2003. Differences in pharmacokinetics between children and adults - II. Children's variability in drug elimination half-lives and in some parameters needed for physiologically-based pharmacokinetic modeling. Risk Anal. 23:117-142.
39. Hew, K. W., and Keller, K. A. 2003. Postnatal anatomical and functional development of the heart: A species comparison. Birth Defects Res. B Dev. Reprod. Toxicol. 68:309-320.
40. Hines, R. N., and McCarver, D. G. 2002. The ontogeny of human drug-metabolizing enzymes: Phase I oxidative enzymes. J. Pharmacol. Exp. Ther. 300:355-360.
41. Holladay, S. D., and Smialowicz, R. J. 2000. Development of the murine and human immune system: Differential effects of immunotoxicants depend on time of exposure. Environ. Health Perspect. 108(suppl.3):463-473.
42. Holsapple, M. P., West, L. J., and Landreth, K. S. 2003. Species comparison of anatomical and functional immune system development. Birth Defects Res. B Dev. Reprod. Toxicol. 68:321-334.
43. Hurtt, M. E., and Sandler, J. D. 2003a. Comparative organ system development: Continuing the series. Birth Defects Res. B Dev. Reprod. Toxicol. 68:307-308.
44. Hurtt, M. E., and Sandler, J. D. 2003b. Comparative organ system development: Introduction. Birth Defects Res. B Dev. Reprod. Toxicol. 68:85.
45. Kavlock, R. J., and Setzer, R. W. 1996. The road to embryologically based dose-response models. Environ. Health Perspect. 104(suppl.1):107-121.
46. Krishnan, K., and Andersen, M. E. 2001. Physiologically based pharmacokinetic modeling in toxicology. In Principles and methods of toxicology, 4 ed., A. W. Hayes, pp. 193-241. Philadelphia: Taylor and Francis.
47. Lau, C., Andersen, M. E., Crawford-Brown, D. J., Kavlock, R. J., Kimmel, C. A., Knudsen, T. B., Muneoka, K., Rogers, J. M., Setzer, R. W., Smith, G., and Tyl, R. 2000. Evaluation of biologically based dose-response modeling for developmental toxicity: A workshop report. Regul. Toxicol. Pharmacol. 31:190-199.
48. Lau, C., Mole, M. L., Copeland, M. F., Rogers, J. M., Kavlock, R. J., Shuey, D. L., Cameron, A. M., Ellis, D. H., Logsdon, T. R., Merriman, J., and Setzer, J. W. 2001. Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: Acquisition of experimental data. Toxicol. Sci. 59:37-48.
49. Leroux, B. G., Leisenring, W. M., Moolgavkar, S. H., and Faustman, E. M. 1996. A biologically-based dose-response model for developmental toxicology. Risk Anal. 16:449-458.
50. Loebstein, R., Lalkin, A., and Koren, G. 1997. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin. Pharmacokinet. 33:328-343.
51. Luecke, R. H., Wosilait, W. D., Pearce, B. A., and Young, J. F. 1994. A physiologically based pharmacokinetic computer model for human pregnancy. Teratology 49:90-103.
52. Luecke, R. H., Wosilait, W. D., and Young, J. F. 1997. Mathematical analysis for teratogenic sensitivity. Teratology 55:373-380.
53. Luecke, R. H., Wosilait, W. D., and Young, J. F. 1999. Mathematical modeling of human embryonic and fetal growth rates. Growth Dev. Aging 63:49-59.
54. Marty, M. S., Chapin, R. E., Parks, L. G., and Thorsrud, B. A. 2003. Development and maturation of the male reproductive system. Birth Defects Res. B Dev. Reprod. Toxicol. 68:125-136.
55. McCarver, D. G., and Hines, R. N. 2002. The ontogeny of human drug-metabolizing enzymes: Phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther. 300:361-366.
56. McLachlan, J. C. 1999. The use of models and metaphors in developmental biology. Endeavour 23:51-55.
57. McNamara, P. J., and Alcorn, J. 2002. Protein binding predictions in infants. AAPS Pharm. Sci. 4:E4.
58. Mendel, C. M. 1992. The free hormone hypothesis: Distinction from the free hormone transport hypothesis. J. Androl. 13:107-116.
59. Naciff J. M., Jump, M. L., Torontali, S. M., Carr, G. J., Tiesman, J. P., Overmann, G. J., and Daston, G. P. 2002. Gene expression profile induced by 17-alpha-ethynyl estradiol, bisphenol A, and genistein in the developing female reproductive system of the rat. Toxicol. Sci. 68:184-199.
60. Naciff, J. M., Overmann, G. J., Torontali, S. M., Carr, G. J., Tiesman, J. P., Richardson, B. D., and Daston, G. P. 2003. Gene expression profile induced by 17 alpha-ethynyl estradiol in the prepubertal female reproductive system of the rat. Toxicol. Sci. 72:314-330.
61. Pinkerton, K. E., and Joad, J. P. 2000. The mammalian respiratory system and critical windows of exposure for children's health. Environ. Health Perspect. 108(suppl. 3):457-462.
62. Price, K., Haddad, S., and Krishnan, K. 2003. Physiological modeling of age-specific changes in the pharmacokinetics of organic chemicals in children. J. Toxicol. Environ. Health A 66:417-433.
63. Pryor, J. L., Hughes, C., Foster, W., Hales, B. F., and Robaire, B. 2000. Critical windows of exposure for children's health: The reproductive system in animals and humans. Environ. Health Perspect. 108(suppl.3):491-503.
64. Renwick, A. B., Watts, P. S., Edwards, R. J., Barton, P. T., Guyonnet, I., Price, R. J., Tredger, J. M., Pelkonen, O., Boobis, A. R., and Lake, B. G. 2000. Differential maintenance of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug. Metab. Dispos. 28:1202-1209.
65. Rice, D., and Barone, S., Jr. 2000. Critical periods of vulnerability for the developing nervous system: Evidence from humans and animal models. Environ. Health Perspect. 108(suppl. 3):511-533.
66. Rice, J. M., and Ward, J. M. 1982. Age dependence of susceptibility to carcinogenesis in the nervous system. Ann. NY Acad. Sci. 381:274-289.
67. Sadler, T. W. 2000. Susceptible periods during embryogenesis of the heart and endocrine glands. Environ. Health Perspect. 108(suppl.3):555-561.
68. Selevan, S. G., Kimmel, C. A., and Mendola, P. 2000. Identifying critical windows of exposure for children's health. Environ. Health Perspect. 108(suppl. 3):451-455.
69. Setzer, R. W., Lau, C., Mole, M. L., Copeland, M. F., Rogers, J. M., and Kavlock, R. J. 2001. Toward a biologically based dose-response model for developmental toxicity of 5-fluorouracil in the rat: A mathematical construct. Toxicol. Sci. 59:49-58.
70. Teeguarden, J. G., and Barton, H. A. 2004. Computational modeling of serum binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds. Risk Anal. 24:753-772.
71. Vesselinovitch, S. D. 1983. Perinatal hepatocarcinogenesis. Biol. Res. Pregnancy Perinatol. 4:22-25.
72. Zoetis, T., and Hurtt, M. E. 2003. Species comparison of anatomical and functional renal development. Birth Defects Res. B Dev. Reprod. Toxicol. 68:111-120.